Diabetes, a chronic disease occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. The current therapeutic agents for type-2 diabetes are associated with some side effects like sudden hypoglycemia, weight loss etc. The global prevalence of diabetes is estimated to be 9% among adults. DPP-4 inhibitors are a new class of oral hypoglycemics that block DPP-4 enzyme and are used to treat diabetes mellitus type-21. DPP-4 inhibitors like sitagliptin has relatively less side effects, hence in present study 32 compounds containing benzofuran ring were designed and their interaction with DPP-4 enzyme studied using Schrodinger small molecule drug discovery suite (Maestro 10.3).
Loading....